| Literature DB >> 25573990 |
Roberta Zappasodi1, Giusi Ruggiero1, Carla Guarnotta2, Monica Tortoreto3, Cristina Tringali4, Alessandra Cavanè1, Antonello D Cabras5, Lorenzo Castagnoli6, Bruno Venerando4, Nadia Zaffaroni3, Alessandro M Gianni7, Filippo De Braud1, Claudio Tripodo2, Serenella M Pupa6, Massimo Di Nicola1.
Abstract
We have shown that human B-cell non-Hodgkin lymphomas (B-NHLs) express heat shock protein (HSP)H1/105 in function of their aggressiveness. Here, we now clarify its role as a functional B-NHL target by testing the hypothesis that it promotes the stabilization of key lymphoma oncoproteins. HSPH1 silencing in 4 models of aggressive B-NHLs was paralleled by Bcl-6 and c-Myc downregulation. In vitro and in vivo analysis of HSPH1-silenced Namalwa cells showed that this effect was associated with a significant growth delay and the loss of tumorigenicity when 10(4) cells were injected into mice. Interestingly, we found that HSPH1 physically interacts with c-Myc and Bcl-6 in both Namalwa cells and primary aggressive B-NHLs. Accordingly, expression of HSPH1 and either c-Myc or Bcl-6 positively correlated in these diseases. Our study indicates that HSPH1 concurrently favors the expression of 2 key lymphoma oncoproteins, thus confirming its candidacy as a valuable therapeutic target of aggressive B-NHLs.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25573990 DOI: 10.1182/blood-2014-07-590034
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113